Broadcast Date: January 26, 2021
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Vaccines and drug products are being developed with a higher sense of urgency but with even greater scrutiny by regulatory agencies. While techniques and hardware have evolved, there are ways to complement these advances by building quality, safety, and consistency into end products with the proper selection of starting materials and continuing on to the final formulary.

This GEN webinar will discuss the real contamination risks described in a recent Nature Biotechnology study and how companies are rising to this challenge through a better selection of components and excipients. Furthermore, a study in Biotechnology and Bioengineering demonstrates the performance of recombinant proteins in cell expansion and virus production. Data will be presented, and focus will be given to how characterizing blood-free components can enhance and accelerate the development of vaccines.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.

Randall Alfano, PhD
Randall Alfano, PhD
Vice President, Product Development
InVitria
Marcus Curl
Marcus Curl
Director, Product Applications
InVitria

Invitria logo

This site uses Akismet to reduce spam. Learn how your comment data is processed.